Heat shock protein 90 - a potential target in the treatment of human acute myelogenous leukemia.

Abstract:

:Heat shock proteins (HSPs) are molecular chaperones that stabilize folding and conformation of normal as well as oncogenic proteins. These chaperones thereby prevent the formation of protein aggregates. HSPs are often overexpressed in human malignancies, including AML. HSP90 is the main chaperon required for the stabilization of multiple oncogenic kinases involved in the development of acute myelogenous leukemia (AML). HSP90 client proteins are involved in the regulation of apoptosis, proliferation, autophagy and cell cycle progression; several of these proteins are in addition considered as possible therapeutic targets for the treatment of AML. HSP90 inhibition thereby offers the possibility to modulate several intracellular regulatory pathways through targeting of a single molecule. Several direct inhibitors of HSP90 have been developed, and they are classified into four groups: benzoquinon ansamycines and their derivatives, radicicol and its derivates, small synthetic inhibitors and a final group of other inhibitors. The HSP90 activity is regulated by posttranscriptional modulation; HSP90 inhibition can thereby be indirectly achieved through increased acetylation caused by histone deacetylase inhibitors. Many of these agents have entered phase I/II clinical trials, and the results from these initial studies have documented that HSP90 inhibition can mediate antileukemic effects in vivo. However, one would expect immunosuppressive side effects because HSP90 inhibitors have both direct and indirect inhibitory effects on T cell activation. Thus, future clinical studies are needed to clarify the efficiency and toxicity of HSP90 inhibitors in the treatment of human AML, including studies where HSP90 inhibitors are combined with conventional chemotherapy.

authors

Reikvam H,Ersvaer E,Bruserud O

doi

10.2174/156800909789271486

subject

Has Abstract

pub_date

2009-09-01 00:00:00

pages

761-76

issue

6

eissn

1568-0096

issn

1873-5576

journal_volume

9

pub_type

杂志文章,评审
  • Role of ABC transporters in the chemoresistance of human gliomas.

    abstract::Malignant gliomas are frequently chemoresistant and this resistance seems to depend on at least two mechanisms. First, the poor penetration of many anticancer drugs across the blood-brain barrier (BBB), the blood-cerebrospinal fluid barrier (BCSFB) and blood-tumor barrier (BTB), due to their interaction with several A...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/156800906777723930

    authors: Declèves X,Amiel A,Delattre JY,Scherrmann JM

    更新日期:2006-08-01 00:00:00

  • Targeting the STAT pathway in head and neck cancer: recent advances and future prospects.

    abstract::Head and neck cancer, the sixth most common type of cancer worldwide, is associated with a dismal prognosis that has minimally improved during the last few decades. Future advances in the treatment and prognosis of this fatal disease largely rely upon a better understanding of the molecular events that underlie tumor ...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/1568009043332736

    authors: Nikitakis NG,Siavash H,Sauk JJ

    更新日期:2004-12-01 00:00:00

  • Tumor-targeted inhibition by a novel strategy - mimoretrovirus expressing siRNA targeting the Pokemon gene.

    abstract::Pokemon gene has crucial but versatile functions in cell differentiation, proliferation and tumorigenesis. It is a master regulator of the ARF-HDM2-p53 and Rb-E2F pathways. The facts that the expression of Pokemon is essential for tumor formation and many kinds of tumors over-express the Pokemon gene make it an attrac...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章

    doi:10.2174/156800910793357907

    authors: Tian Z,Wang H,Jia Z,Shi J,Tang J,Mao L,Liu H,Deng Y,He Y,Ruan Z,Li J,Wu Y,Ni B

    更新日期:2010-12-01 00:00:00

  • Emerging role of endoglin (CD105) as a marker of angiogenesis with clinical potential in human malignancies.

    abstract::Angiogenesis is crucial for tumor development and progression, and antiangiogenetic therapy represents a promising approach for cancer treatment. Thus, the in-depth understanding of the molecular mechanism(s) regulating angiogenesis, together with the characterization of molecules expressed by endothelial cells and in...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/1568009033481741

    authors: Fonsatti E,Sigalotti L,Arslan P,Altomonte M,Maio M

    更新日期:2003-12-01 00:00:00

  • Targeting carcinogen metabolism by dietary cancer preventive compounds.

    abstract::Prevention is one of the most important and promising strategies to control cancer. Many dietary bioactive compounds, mostly phytochemicals, have been found to decrease the risk of carcinogenesis. Modulating the metabolism and disposition pathways of carcinogens represents one of the major mechanisms by which dietary ...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/156800907781386669

    authors: Yu S,Kong AN

    更新日期:2007-08-01 00:00:00

  • Pharmacogenomics opportunities in nuclear receptor targeted cancer therapy.

    abstract::Nuclear Hormone Receptors (NR) represent one of the most promising protein families in terms of therapeutic applications. These transcription factors are naturally switched on and off by small molecule hormones presenting physico-chemical properties very similar to therapeutic chemical entities. NRs represent therefor...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/1568009023333845

    authors: Schapira M

    更新日期:2002-09-01 00:00:00

  • Identifying molecular targets mediating the anticancer activity of histone deacetylase inhibitors: a work in progress.

    abstract::The anticancer properties of histone deacetylase inhibitors have been known for some time. However, it is only recently that the functional identities of the intracellular targets mediating the anticancer properties have started to be revealed. These targets appear to play significant roles in cell cycle control, apop...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/1568009023333818

    authors: Gabrielli BG,Johnstone RW,Saunders NA

    更新日期:2002-12-01 00:00:00

  • Cyclopentenyl cytosine (CPEC): an overview of its in vitro and in vivo activity.

    abstract::The experimental cytotoxic drug cyclopentenyl cytosine (CPEC) is an analogue of cytidine. Besides its antiviral effect, its potential use in the treatment of cancer has become an important area of research. CPEC is activated by intracellular phosphorylation ultimately forming its metabolite CPEC-TP. CPEC-TP is a non c...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/156800907781386579

    authors: Schimmel KJ,Gelderblom H,Guchelaar HJ

    更新日期:2007-08-01 00:00:00

  • Lipoamino acid prodrugs of paclitaxel: synthesis and cytotoxicity evaluation on human anaplastic thyroid carcinoma cells.

    abstract::Lipophilic derivatives of the anticancer drug paclitaxel (PTX) were prepared by means of its conjugation to lipoamino acid (LAA) residues, with the aim of increasing drug accumulation in tumor cells. PTX was linked to the methyl esters of norleucine (C6) or 2-aminodecanoic acid (C10). A succinic acid group was used as...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章

    doi:10.2174/156800909787580944

    authors: Pignatello R,Paolino D,Pantò V,Pistară V,Calvagno MG,Russo D,Puglisi G,Fresta M

    更新日期:2009-03-01 00:00:00

  • The SCF-type E3 Ubiquitin Ligases as Cancer Targets.

    abstract::The ubiquitin system controls protein stability and function. F-box proteins form SCF (SKP1-Cullin1-F-box protein)-type ubiquitin (E3) ligases to selectively target their substrates for degradation via the ubiquitin-proteasome pathway. Here, we review F-box proteins associated with cancer development. S-phase kinase-a...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/1568009616666151112122231

    authors: Kitagawa K,Kitagawa M

    更新日期:2016-01-01 00:00:00

  • Role of angiogenesis inhibitors in colorectal cancer: sensitive and insensitive tumors.

    abstract::Angiogenesis is a key factor in the carcinogenesis process. In oncological practice, angiogenesis inhibition, mainly through the blockade of the VEGF family and its receptors, has been robustly demonstrated to produce clinical benefits and, in specific disease subsets such as colorectal cancer, to extend the overall s...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/156800912800190929

    authors: Bagnasco L,Piras D,Parodi S,Bauer I,Zoppoli G,Patrone F,Ballestrero A

    更新日期:2012-05-01 00:00:00

  • New strategies in the chemotherapy of leukemia: eradicating cancer stem cells in chronic myeloid leukemia.

    abstract::Chronic myeloid leukemia (CML) is a myeloproliferative disorder caused by the Philadelphia-positive chromosome deriving from a translocation between chromosomes 22 and 9. The oncogenic product of this aberrant chromosome is the constitutively active tyrosine kinase BCR-ABL that is responsible for leukemic cell growth,...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/156800912800673239

    authors: Stefanachi A,Leonetti F,Nicolotti O,Catto M,Pisani L,Cellamare S,Altomare C,Carotti A

    更新日期:2012-06-01 00:00:00

  • Human mesenchymal stem cells (hMSCs) as targets of DNA damaging agents in cancer therapy.

    abstract::Human mesenchymal stem cells (hMSCs) consist of cells that can differentiate into mesenchymal tissues, including osteoblasts, adipocytes and chondrocytes. hMSCs constitute a particular stem cell niche in the stromal compartment of the bone marrow, and also play a role in maintaining the normal function of haematopoiet...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/156800910791208553

    authors: Cruet-Hennequart S,Prendergast AM,Barry FP,Carty MP

    更新日期:2010-06-01 00:00:00

  • Cell-penetrating Peptides for Cancer-targeting Therapy and Imaging.

    abstract::Cell-penetrating peptides (CPPs) have been previously shown to be powerful transport vector tools for the delivery of a large variety of cargoes through the cell membrane, as well as other physiological membranes. And since they're relatively cell-, receptor- and energy-independent, CPPs have unique advantages in faci...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/1568009615666150211104524

    authors: Wang W,Abbad S,Zhang Z,Wang S,Zhou J,Lv H

    更新日期:2015-01-01 00:00:00

  • Anti-angiogenic targets in the treatment of advanced renal cell carcinoma.

    abstract::Drugs that target the vascular endothelial growth factor (VEGF) and platelet derived growth factor (PDGF) pathways have revolutionized the treatment of patients with metastatic renal cell cancer (RCC). Patients with clear cell RCC often have mutations or silencing of the von Hippel Lindau gene leading to an accumulati...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/156800908786733450

    authors: Heng DY,Bukowski RM

    更新日期:2008-12-01 00:00:00

  • Targeted therapies in non-small cell lung cancer: proven concepts and unfulfilled promises.

    abstract::Targeted therapies focus on signaling pathways in cancer cells and other molecular processes involved in oncogenesis. Recent approaches affect the following major groups: the epidermal growth factor receptor (EGFR)-family, angiogenesis, the eicosanoid pathway, the PKC/ Ras/ MAPK pathway, the proteasome and inducers of...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/156800906777441780

    authors: Auberger J,Loeffler-Ragg J,Wurzer W,Hilbe W

    更新日期:2006-06-01 00:00:00

  • MicroRNAs in the pathobiology of multiple myeloma.

    abstract::MicroRNAs (miRNAs) are small non-coding RNAs that bind to the 3'untranslated region of target mRNAs and lead to translation repression or mRNA degradation, thus regulating important cell processes. MiRNA deregulation has been identified in virtually all types of cancer, and miRNA profiling has proved useful in cancer ...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/156800912802429274

    authors: Lionetti M,Agnelli L,Lombardi L,Tassone P,Neri A

    更新日期:2012-09-01 00:00:00

  • Alternative splicing in chronic myeloid leukemia (CML): a novel therapeutic target?

    abstract::Although the imatinib based therapy of chronic myeloid leukemia (CML) represents a triumph of medicine, not all patients with CML benefit from this drug due to the development of resistance and intolerance. The interruption of imatinib treatment is often followed by clinical relapse, suggesting a failure in the killin...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/15680096113139990083

    authors: Adamia S,Pilarski PM,Bar-Natan M,Stone RM,Griffin JD

    更新日期:2013-09-01 00:00:00

  • Targeting Key Metabolic Enzymes Involved in Lipid and Protein Biosyntheses for Breast Anticancer Therapies.

    abstract::The evolution of genomic research enabled the genetic and molecular profiling of breast cancer and revealed the profound complexity and heterogeneity of this disease. Subtypes of breast cancer characterized by mutations and/or amplifications of some proto-oncogenes are associated with an increased rate of recurrence a...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/1568009616666160603123014

    authors: Guerram M,Hamdi AM,Zhang LY,Jiang Z

    更新日期:2017-01-01 00:00:00

  • Polysialyltransferase: a new target in metastatic cancer.

    abstract::Polysialic acid (polySia) is a carbohydrate polymer critical for neuronal cell migration and axon pathfinding in embryonic development. Besides brain regions requiring persistent neuronal plasticity, polySia is essentially absent from the adult body. However, polySia is aberrantly re-expressed on many tumours, where i...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/156800912803251225

    authors: Falconer RA,Errington RJ,Shnyder SD,Smith PJ,Patterson LH

    更新日期:2012-10-01 00:00:00

  • Myelodysplastic syndromes: review of pathophysiology and current novel treatment approaches.

    abstract::Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal disorders of hematopoietic progenitors manifest by cytopenias, bleeding, infection, and potential for progression to acute myelogenous leukemia. The wide spectrum of clinical manifestations, including variability in illness severity and potential for ...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/156800907781662284

    authors: Warlick ED,Smith BD

    更新日期:2007-09-01 00:00:00

  • Targeting of Hsp32 in solid tumors and leukemias: a novel approach to optimize anticancer therapy.

    abstract::Heat shock protein 32 (Hsp32), also known as heme oxygenase-1 (HO-1), is a stress-related anti-apoptotic molecule, that has been implicated in enhanced survival of neoplastic cells and in drug-resistance. We here show that Hsp32 is expressed in most solid tumors and hematopoietic neoplasms and may be employed as a new...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章

    doi:10.2174/156800909789057024

    authors: Gleixner KV,Mayerhofer M,Vales A,Gruze A,Hörmann G,Cerny-Reiterer S,Lackner E,Hadzijusufovic E,Herrmann H,Iyer AK,Krauth MT,Pickl WF,Marian B,Panzer-Grümayer R,Sillaber C,Maeda H,Zielinski C,Valent P

    更新日期:2009-08-01 00:00:00

  • Matrix metalloproteinases as therapeutic targets in cancer.

    abstract::Degradation of extracellular matrix is crucial for malignant tumor growth, invasion, metastasis and angiogenesis. Matrix metalloproteinases (MMPs) are a family of zinc-dependent neutral endopeptidases collectively capable of degrading essentially all matrix components. Elevated levels of distinct MMPs can be detected ...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/1568009053765799

    authors: Vihinen P,Ala-aho R,Kähäri VM

    更新日期:2005-05-01 00:00:00

  • Bid stands at the crossroad of stress-response pathways.

    abstract::Bid, a BH3-only Bcl-2 family member, is proven to be a pivotal molecule for the regulation of tumorigenesis by its multiple functions in promoting apoptosis, survival and proliferation. Growing evidence supports that Bid has double roles with respect to stress-response. In most cases it functions in a truncated form, ...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/156800910791859515

    authors: Song G,Chen GG,Hu T,Lai PB

    更新日期:2010-09-01 00:00:00

  • 11-Phenylundeca-5Z,9Z-dienoic Acid: Stereoselective Synthesis and Dual Topoisomerase I/IIα Inhibition.

    abstract::(5Z,9Z)-11-Phenylundeca-5,9-dienoic acid was stereoselectively synthesized, based on original cross-cyclomagnesiation of 2-(hepta-5,6-dien-1-yloxy)tetrahydro-2H-pyran and buta-2,3-dien-1-ylbenzene with EtMgBr in the presence of the Cp2TiCl2 catalyst giving 2,5-dialkylydenemagnesacyclopentane in 86% yield. The acid hyd...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章

    doi:10.2174/1568009615666150506093155

    authors: D'yakonov VA,Dzhemileva LU,Makarov AA,Mulyukova AR,Baevd DS,Khusnutdinova EK,Tolstikova TG,Dzhemilev UM

    更新日期:2015-01-01 00:00:00

  • CX-4945, a Selective Inhibitor of Casein Kinase 2, Synergizes with B Cell Receptor Signaling Inhibitors in Inducing Diffuse Large B Cell Lymphoma Cell Death.

    abstract:BACKGROUND:Approximately one third of Diffuse Large B cell Lymphomas (DLBCL) are refractory or relapse. Novel therapeutic approaches under scrutiny include inhibitors of B-cell receptor (BCR) signaling. Protein kinase CK2 propels survival, proliferation and stress response in solid and hematologic malignancies and prom...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章

    doi:10.2174/1568009617666170427110450

    authors: Mandato E,Nunes SC,Zaffino F,Casellato A,Macaccaro P,Tubi LQ,Visentin A,Trentin L,Semenzato G,Piazza F

    更新日期:2018-01-01 00:00:00

  • Oncolytic Tanapoxvirus Expressing Interleukin-2 is Capable of Inducing the Regression of Human Melanoma Tumors in the Absence of T Cells.

    abstract:BACKGROUND:Oncolytic viruses (OVs), which preferentially infect cancer cells and induce host anti-tumor immune responses, have emerged as an effective melanoma therapy. Tanapoxvirus (TANV), which possesses a large genome and causes mild self-limiting disease in humans, is potentially an ideal OV candidate. Interleukin-...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章

    doi:10.2174/1568009617666170630143931

    authors: Zhang T,Kordish DH,Suryawanshi YR,Eversole RR,Kohler S,Mackenzie CD,Essani K

    更新日期:2018-01-01 00:00:00

  • The clinical applications of heat shock protein inhibitors in cancer - present and future.

    abstract::The potential clinical applications of the prototype first-in-class Hsp90 inhibitor 17AAG and other emerging Hsp90 drugs are very exciting. Rigorously planned and executed clinical trials, incorporating measurement of appropriate biomarkers and pharmocodynamic endpoints are critical for selecting the optimal dose and ...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/1568009033481813

    authors: Banerji U,Judson I,Workman P

    更新日期:2003-10-01 00:00:00

  • Antiproliferative efficacy of angiotensin II receptor blockers in prostate cancer.

    abstract::An apparent low prevalence of cancer in hypertensive patients receiving angiotensin converting enzyme inhibitors is reported; however, the molecular mechanisms have not been elucidated. Angiotensin-II (Ang-II) is well known to be associated with hypertension, as a main peptide of the renin-angiotensin system, and its ...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/1568009054629663

    authors: Uemura H,Nakaigawa N,Ishiguro H,Kubota Y

    更新日期:2005-08-01 00:00:00

  • New drug targets for genomic cancer therapy: successes, limitations, opportunities and future challenges.

    abstract::Cancer drug therapy is undergoing a major transition from the previous pregenomic cytotoxic era to the new postgenomic era. Future mechanism-based therapeutic agents will increasingly be designed to act on molecular targets that are causally involved in the malignant progression of human cancers. Such agents are predi...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/1568009013334269

    authors: Workman P

    更新日期:2001-05-01 00:00:00